Jean-Jacques Grob

9.4k total citations · 1 hit paper
9 papers, 1.6k citations indexed

About

Jean-Jacques Grob is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Jean-Jacques Grob has authored 9 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Molecular Biology and 1 paper in Pathology and Forensic Medicine. Recurrent topics in Jean-Jacques Grob's work include Cutaneous Melanoma Detection and Management (4 papers), CAR-T cell therapy research (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Jean-Jacques Grob is often cited by papers focused on Cutaneous Melanoma Detection and Management (4 papers), CAR-T cell therapy research (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Jean-Jacques Grob collaborates with scholars based in France, United States and Italy. Jean-Jacques Grob's co-authors include Dirk Schadendorf, Jedd D. Wolchok, Vanna Chiarion‐Sileni, Piotr Rutkowski, F. Stephen Hodi, C. Lance Cowey, James Larkin, René González, Christopher D. Lao and Michael Smylie and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and European Journal of Cancer.

In The Last Decade

Jean-Jacques Grob

8 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

2018 1.0k citations F. Stephen Hodi, Vanna Chiarion‐Sileni et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jean-Jacques Grob France	7	1.4k	547	541	243	176	9	1.6k
Ryota Tanaka Japan	21	1.0k 0.8×	311 0.6×	457 0.8×	247 1.0×	225 1.3×	71	1.4k
Franz O. Smith United States	12	2.1k 1.5×	491 0.9×	1.4k 2.6×	282 1.2×	127 0.7×	20	2.4k
Jacopo Pigozzo Italy	22	1.7k 1.2×	590 1.1×	658 1.2×	471 1.9×	119 0.7×	56	2.0k
Roberto Patuzzo Italy	20	957 0.7×	389 0.7×	434 0.8×	110 0.5×	303 1.7×	56	1.3k
Jennifer Landsberg Germany	23	676 0.5×	595 1.1×	454 0.8×	264 1.1×	97 0.6×	58	1.4k
Cécile Pagès France	19	794 0.6×	302 0.6×	232 0.4×	190 0.8×	188 1.1×	53	1.1k
Kenjiro Namikawa Japan	18	920 0.7×	463 0.8×	279 0.5×	167 0.7×	233 1.3×	104	1.2k
Lorenza Di Guardo Italy	15	987 0.7×	360 0.7×	398 0.7×	248 1.0×	75 0.4×	48	1.2k
Anja Gesierich Germany	17	785 0.6×	602 1.1×	239 0.4×	112 0.5×	371 2.1×	64	1.3k
Riccardo Marconcini Italy	17	1000 0.7×	458 0.8×	409 0.8×	189 0.8×	166 0.9×	48	1.3k

Countries citing papers authored by Jean-Jacques Grob

Since Specialization

Citations

This map shows the geographic impact of Jean-Jacques Grob's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean-Jacques Grob with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean-Jacques Grob more than expected).

Fields of papers citing papers by Jean-Jacques Grob

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean-Jacques Grob. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean-Jacques Grob. The network helps show where Jean-Jacques Grob may publish in the future.

Co-authorship network of co-authors of Jean-Jacques Grob

This figure shows the co-authorship network connecting the top 25 collaborators of Jean-Jacques Grob. A scholar is included among the top collaborators of Jean-Jacques Grob based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean-Jacques Grob. Jean-Jacques Grob is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Herms, F., M. Beylot‐Barry, Cendrine Chaffaut, et al.. (2025). Comparison of the tolerability and safety of hedgehog inhibitors in real-life: A cohort of 330 patients with locally advanced basal cell carcinoma.. Journal of Clinical Oncology. 43(16_suppl). 9583–9583.

Ascierto, Paolo A., Michael B. Atkins, Alexander M.M. Eggermont, et al.. (2021). The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020. Journal of Translational Medicine. 19(1). 142–142. 1 indexed citations

Lambert, Jérémy, Alexia Marrel, Sandra P. D’Angelo, et al.. (2020). Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. Patient. 13(4). 457–467. 10 indexed citations

Eggermont, Alexander M.M., Vanna Chiarion‐Sileni, Jean-Jacques Grob, et al.. (2019). Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. European Journal of Cancer. 119. 1–10. 123 indexed citations

Luke, Jason J., Paolo A. Ascierto, Matteo S. Carlino, et al.. (2019). KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncology. 16(3). 4429–4438. 49 indexed citations

Hodi, F. Stephen, Vanna Chiarion‐Sileni, René González, et al.. (2018). Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. The Lancet Oncology. 19(11). 1480–1492. 1009 indexed citations breakdown →

Dréno, Brigitte, Rainer Kunstfeld, Axel Hauschild, et al.. (2017). Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. The Lancet Oncology. 18(3). 404–412. 142 indexed citations

Schadendorf, Dirk, Jedd D. Wolchok, F. Stephen Hodi, et al.. (2017). Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. Journal of Clinical Oncology. 35(34). 3807–3814. 310 indexed citations

González-Castro, V́ıctor, Johan Debayle, Mehdi Rahim, et al.. (2015). Automatic classification of skin lesions using color mathematical morphology-based texture descriptors. Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE. 9534. 953409–953409. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact